



**HAL**  
open science

## **Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction**

Jean-Louis Henry Kerkhoffs, Wim L.J. van Putten, Viera M.J. Novotny, Peter A. W. Te Boekhorst, Martin R. Schipperus, Jaap Jan Zwaginga, Lizzy C.M. van Pampus, Georgine E de Greef, Marleen Luten, Peter C Huijgens, et al.

### ► **To cite this version:**

Jean-Louis Henry Kerkhoffs, Wim L.J. van Putten, Viera M.J. Novotny, Peter A. W. Te Boekhorst, Martin R. Schipperus, et al.. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. *British Journal of Haematology*, 2010, 10.1111/j.1365-2141.2010.08227.x . hal-00552596

**HAL Id: hal-00552596**

**<https://hal.science/hal-00552596>**

Submitted on 6 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction**

Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-00137.R1
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	02-Apr-2010
Complete List of Authors:	Kerkhoffs, Jean-Louis; Sanquin Bloodbank, research and development van Putten, Wim; HOVON Data Centre, Statistics Novotny, Viera; UMC St Radboud, Haematology Te Boekhorst, Peter; Erasmus Medical Center, Hematology Schipperus, Martin; HagaZiekenhuis, Department of Hematology Zwaginga, Jaap Jan; Leiden University Medical Center, Haematology van Pampus, Lizzy; UMC St Radboud, Haematology de Greef, Georgine; Erasmus MC Daniel den Hoed, Hematology Luten, Marleen; HOVON Data Centre, Statistics Huijgens, Peter; VU University medical center, Haematology Brand, Anneke; Leiden University Medical Center, Immunohematology and Blood transfusion van Rhenen, Dick; Sanquin Bloodbank, Research & Development
Key Words:	TRANSFUSION MEDICINE, PLATELETS, HAEMATOLOGICAL ONCOLOGY

1  
2  
3 **Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in**  
4 **plasma or additive solution with and without pathogen reduction**  
5  
6  
7

8  
9  
10 J.L.H. Kerkhoffs<sup>1, 5</sup>, W.L.J. van Putten<sup>2</sup>, V.M.J. Novotny<sup>3</sup>, P.A.W. Te Boekhorst<sup>4</sup>, M.  
11 Schipperus<sup>5</sup>, J.J. Zwaginga<sup>6</sup>, E.C.M. van Pampus<sup>3</sup>, G.E. de Greef<sup>4</sup>, M. Luten<sup>2</sup>, P.C. Huijgens<sup>7</sup>, A.  
12 Brand<sup>1,6</sup>, D.J. van Rhenen<sup>1</sup> on behalf of the Dutch – Belgian HOVON cooperative group.  
13  
14  
15

16  
17  
18 <sup>1</sup>Sanquin Blood Bank, Southwest Region, Rotterdam; <sup>2</sup>Erasmus University Medical Centre,  
19 HOVON Data Centre, Rotterdam; <sup>3</sup>UMC St Radboud, Nijmegen; <sup>4</sup>Erasmus University Medical  
20 Centre ,Rotterdam; <sup>5</sup>Haga Teaching Hospital, The Hague; <sup>6</sup>Leiden University Medical Centre,  
21 Leiden; <sup>7</sup>VU Medical Centre, Amsterdam, The Netherlands.  
22  
23  
24  
25

26  
27 <http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=861>  
28

29  
30 <http://www.controlled-trials.com/ISRCTN88278819/HOVON+82>  
31

32 **Correspondence address:**  
33

34 Jean-Louis H. Kerkhoffs  
35

36 Sanquin Southwest Region  
37

38 Plesmanlaan 1a  
39

40 2333 BZ Leiden  
41

42 E-mail: [j.kerkhoffs@sanquin.nl](mailto:j.kerkhoffs@sanquin.nl)  
43

44 Phone: +31 71 5685062 / +31 6 51180383  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Summary

Pathogen reduction (PR) of platelet products increases costs and available clinical studies are **equivocal** with respect to clinical and haemostatic effectiveness. We conducted a **multicentre**, open-label, randomised, **non-inferiority trial** comparing clinical effectiveness of buffy-coat derived leukoreduced platelet concentrates (PC) stored up to seven days in plasma with platelets stored in platelet additive solution III (PASIII) without and with treatment with amotosalen-HCl/UVA photochemical pathogen reduction (PR-PASIII). Primary endpoint of the study was 1-hour corrected count increment (CCI). Secondary endpoints were 24-hour CCI, bleeding, transfusion requirement of red cells and **PC**, platelet transfusion interval and adverse transfusion reactions. Compared to plasma-**PC**, in the intention to treat analysis of 278 evaluable patients the mean difference for the 1-hour CCI of PR-PASIII-**PC** and PASIII-**PC** was -31% ( $p < 0.0001$ ) and -9% ( $p = \text{n.s.}$ ), respectively. Twenty-seven patients (32%) had bleeding events in the PR-PASIII arm, as compared to 19 (19%) in the plasma arm and 14 (15%) in the PASIII arm ( $p = 0.034$ ). Despite the potential advantages of pathogen (and leukocyte) inactivation of **amotosalen-HCl/UVA-treated** platelet products, their clinical efficacy is inferior to platelets stored in plasma, warranting a critical reappraisal of employing this technique for clinical use.

**Keywords:** Platelet, Buffy-coat, **Amotosalen/UVA** Pathogen Reduction, Efficacy.

1  
2  
3 For **the** generally accepted indications for treatment and prevention of bleeding, millions  
4 of platelet products are **transfused yearly**, warranting vigilance towards emerging  
5 logistical problems and safety issues (Slichter, 2007; Stroncek & Rebutta, 2007). Donor  
6 counselling and screening, including molecular techniques, **have** reduced the risk of  
7 transmission of hepatitis B, hepatitis C, HIV, HTLV-I and -II. **However, despite the**  
8 **bacterial culture of platelet products, a risk of 1 in 25,000 platelet transfusions for**  
9 **transfusion-related sepsis still remains** (Goodnough *et al*, 1999; Kuehnert *et al*, Dodd  
10 *et al*, 2002; Blajchman *et al*, 2005; Schrezenmeier *et al*, 2007). Availability of platelets  
11 and reduction of costs due to **reduced** outdateding would benefit from **extending** the  
12 storage time of platelet products, **which is** hampered **mainly** by the risk of bacterial  
13 growth beyond 5 days **of** storage (Lee *et al*, 2003). Pathogen reduction (PR) has been  
14 shown to be very effective for the inactivation of several viruses and bacteria (Lin *et al*,  
15 2004; Lin *et al*, 2005). Moreover, PR might also comprise a solution for emerging  
16 pathogens, CMV and an alternative for  **$\gamma$ -irradiation** for **the** prevention of graft-versus-  
17 host-disease (Grass *et al*, 1999; Lin *et al*, 2001). Several countries consider implementing  
18 PR as a standard for all platelet products, but concerns still exist with regard to clinical  
19 efficacy, potential long-term toxicity as well as uncertainty whether PR- platelet products  
20 can be stored longer than 5 days (Council of Europe, 2001; Simonsen *et al*, 2006).  
21 Although PR platelet products using amotosalen-HCl and UVA **fulfil** standard release  
22 criteria up to 7 days of storage, this treatment results in considerable metabolic  
23 deterioration, increased platelet activation during storage and inconsistent findings by in-  
24 vitro haemostatic assessment (van Rhenen *et al*, 2000; Picker *et al*, 2004; Janetzko *et al*,  
25 2004; Jansen *et al*, 2004; Lozano *et al*, 2007; Apolseth *et al*, 2007; van der Meer *et al*,  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2009). Nevertheless, transfusion in thrombocytopenic patients corrected prolonged  
4 bleeding times (Slichter *et al*, 2006). Radiolabeled, autologous 5 days stored **amotosalen-**  
5  
6 **HCl/UVA-treated platelets** showed a significant lower recovery and reduction in  
7  
8 survival time as compared to platelets stored in PASIII additive solution (Snyder *et al*,  
9  
10 2004). Three randomised controlled trials have been performed using **amotosalen-**  
11  
12 **HCl/UVA-treated** platelet concentrates (**PC**) (van Rhenen *et al*, 2003; McCullough *et al*,  
13  
14 2004; Janetzko *et al*, 2005). In the SPRINT trial (645 patients), using aphaeresis **PC**  
15  
16 stored in plasma as control, significantly lower post transfusion platelet increments were  
17  
18 found, combined with a reduced transfusion interval and an increased rate of transfusion  
19  
20 failure (McCullough *et al*, 2004). **The EuroSPRITE trial (103 patients) reported no**  
21  
22 **significant differences with regard to transfusion efficacy, however the control arm**  
23  
24 **of this study used buffy-coat derived platelets stored in plasma as well as in additive**  
25  
26 **solution (PASII) for approximately half of the transfusions (van Rhenen *et al*, 2003).**  
27  
28 **In a previous RCT we have shown that PASII PC have a 20% lower corrected count**  
29  
30 **increment as compared to plasma PC, which might have masked a relevant**  
31  
32 **difference (Kerkhoffs *et al*, 2006).** A third small trial with 43 patients showed a  
33  
34 **borderline** significant reduction in transfusion efficacy (Janetzko *et al*, 2005). None of  
35  
36 these trials reported inferior haemostatic efficacy. Before the implementation of pathogen  
37  
38 reduced platelet products, extending storage time to 7 days while maintaining clinical  
39  
40 efficacy is an important aspect **to compensate** for the additional costs of the procedure.  
41  
42 We performed a multicentre open-label, randomised clinical trial to study the clinical  
43  
44 efficacy in terms of transfusion response of pooled, random donor **PC** stored up to seven  
45  
46 days in platelet additive solution (Intersol, Fenwal, Inc., Lake Zurich, IL, USA) without  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 additional PR (PASIII) and with amotosalen-HCl/UVA photochemical PR (PR-PASIII,  
4 Intercept Blood System, Cerus Corporation, Concord, CA, USA), compared to platelets  
5 stored in plasma.  
6  
7  
8  
9

## 10 11 12 **Methods**

### 13 14 15 16 17 Study design

18  
19 The study was designed as a prospective, randomised open-label non-inferiority trial in  
20 haemato-oncological patients with thrombocytopenia or expected to be thrombocytopenic  
21 caused by myelosuppression. Patients were included at the haematology wards of eight  
22 Dutch hospitals. The study protocol and consent forms were approved both by a **central**  
23 **ethics committee as well as local institutional review boards**. The study was conducted  
24 according to the ICH-GCP guidelines and the declaration of Helsinki. During the study  
25 all centres were audited and trial conduct was monitored by an independent organisation.  
26  
27 All patients older than 18 years, having a haemato-oncological disease, were eligible for  
28 inclusion if they were expected to receive 2 or more platelet transfusions. Exclusion  
29 criteria were immunological refractoriness to random platelet transfusions due to HLA-  
30 and/or HPA-antibodies or clinical relevant auto-antibodies, pregnancy (or lactating) and  
31 previous inclusion in this study. After informed consent eligible patients were registered  
32 and randomised, stratified by centre, before start of platelet transfusions in a 1:1:1 ratio to  
33 receive per protocol up to a maximum of 5 platelet transfusions with Plasma-PC, PASIII-  
34 PC or PR-PASIII-PC in a period of maximal 42 days. Off protocol platelet transfusions  
35 were allowed during the study period in case of non-availability of the correct  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 component. Apart from normal completion, reasons to go off study were refusal to  
4  
5 continue by the patient or treating physician, intercurrent death and immunological  
6  
7 refractoriness.  
8  
9

### 10 11 12 Platelet products, transfusions and monitoring

13  
14 All products were produced by the Sanquin Blood Bank. PCs were prepared from 5  
15  
16 pooled whole-blood buffy-coats (BC) with the same ABO-blood group using standard  
17  
18 procedures and with regard to pathogen reduction using manufacturer's instructions (van  
19  
20 Rhenen *et al*, 2003; Kerkhoffs *et al*, 2006). **Samples were obtained prior to storage to**  
21  
22 **measure platelet content. Samples of all products were cultured for 7 days using the**  
23  
24 **BacT/Alert culturing system (BioMerieux, Boxtel, the Netherlands).** All products  
25  
26 were stored with gentle agitation at 20–24 °C up to seven days. The PCs were  $\gamma$ -irradiated  
27  
28 if requested by the hospital.  
29  
30  
31  
32  
33

34 Indications for platelet transfusions were divided into platelet count-based prophylaxis,  
35  
36 intervention related prophylaxis and treatment of bleeding. Generally accepted guidelines  
37  
38 were used as guidance for the indication of platelet transfusions. If or when a transfusion  
39  
40 was ordered was determined by the treating physician. In summary, in stable, non-  
41  
42 bleeding patients a platelet transfusion was advised to maintain the platelet count  $\geq 10 \times$   
43  
44  $10^9/l$  and  $\geq 40 \times 10^9/l$  when these patients receive anti-coagulant therapy or treatment  
45  
46 with anti-thymocyte globulin. A transfusion trigger of  $40 \times 10^9/l$  was recommended in  
47  
48 endoscopic evaluation of the gastrointestinal or respiratory tract, when no biopsies **are**  
49  
50 performed, diagnostic pleural or peritoneal puncture with a thin needle, lumbar puncture,  
51  
52 extraction of a central venous catheter and minor surgical interventions. A trigger of  $60 \times$   
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 10<sup>9</sup>/l was recommended in case of bleeding, endoscopic evaluation with biopsies, dental  
4 extractions, placement of a central venous catheter and major surgical interventions, with  
5 the exception of neurosurgery and cardiac surgery. In case of cerebral bleeding, diffuse  
6 alveolar haemorrhage, neurosurgery and cardiac surgery a trigger of 100 x 10<sup>9</sup>/l was  
7 recommended. A pretransfusion platelet count was preferably measured just before  
8 transfusion up till a maximum of 6 hours before transfusion. A 1-hour posttransfusion  
9 platelet count was measured between 10 and 120 minutes after transfusion and a 24-hour  
10 post transfusion platelet count was measured between 16 and 28 hours after transfusion.  
11 The CCI was calculated as follows:  $CCI_{1/24\text{ h}} = [(post\ transfusion\ platelet\ count_{1/24\text{ h}} - pre$   
12  $transfusion\ platelet\ count\ (x\ 10^9/L)) \times body\ surface\ area\ (m^2)] / platelet\ dose \times 10^{11}$ .  
13  
14 Transfusions given shortly after one another without platelet counts between the  
15 transfusions are referred to as **multi-dose** transfusions and analysed as a single  
16 transfusion. If available, ABO-identical **PC** were used, although minor- and major  
17 incompatible **PC** were not excluded. Platelet transfusion failure was defined as a 1-hour  
18 corrected count increment (CCI) below 7.5 and/or and 24-hour CCI below 4.5  
19 (**Kerkhoffs et al, 2006**). Immunological refractoriness was defined as the occurrence of  
20 transfusion failure of two consecutive ABO-matched random platelet transfusions  
21 combined with existence of HLA- and/or HPA-alloantibodies.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 Study endpoints

49  
50 The primary endpoint was the 1-hour CCI. Secondary endpoints were 24-hour CCI,  
51 bleeding, the transfusion requirement of red cells and PCs, platelet transfusion interval  
52 and adverse transfusion reactions. The following characteristics were recorded at entry:  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 gender, age, blood group, haematological disease and treatment phase, WHO  
4 performance status, existence of enlarged spleen, transfusion history, treatment with anti-  
5 coagulation, medical history, medication, bleeding and presence of active infection. The  
6 following characteristics were recorded at each transfusion: the reason of the transfusion  
7 (trigger, bleeding or intervention), the blood group of the PC, presence of fever, presence  
8 of infection (graded according to the CTCAE), presence of mucosal damage, and use of  
9 acetaminophen, steroids or **antihistamines**. Patients were evaluated daily by trained  
10 personnel to observe, describe and grade bleeding complications at 8 defined sites  
11 according to the CTCAE under supervision of the local investigator  
12 (<http://ctep.info.nih.gov/reporting/ctc.html>). **In short grade 1 or minor bleeding**  
13 **comprises petechiae, minimal or microscopic bleeding not requiring interventions.**  
14 **Grade 2 bleeding is defined as gross, symptomatic bleeding for which minimal**  
15 **intervention (i.e. aspiration, cauterisation, irrigation of the urinary tract) is**  
16 **indicated. Grade 3 is severe bleeding requiring red cell transfusions and/or major**  
17 **interventions. Generalized petechiae/purpura as well as retinal bleeding with visual**  
18 **impairment also is classified as grade 3. Catastrophic bleeding defines grade 4, as**  
19 **does CNS bleeding causing neurologic deficit or disability. Lethal bleeding is**  
20 **classified as grade 5. All major bleeding complications were reviewed centrally.**  
21 Infections were scored in case of positive cultures or if a focus was likely as shown by  
22 clinical or radiological examination. Apart from haematological parameters, PT, aPTT  
23 and fibrinogen, were measured regularly. Some centres performed routine **periodic**  
24 serological testing of HLA- and/or HPA-alloantibodies, whereas other centres performed  
25 these tests only on indication.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Reporting of serious adverse events and Data Safety Monitoring Board

Serious adverse events (SAE) for the purpose of this study were defined as any untoward medical occurrence that resulted in death, a life-threatening event or any other medical condition which might jeopardize the patient or required intervention to prevent more serious sequelae. SAE reporting was mandatory within 24-hours of the initial observation. An independent Data Safety Monitoring Board (DSMB) was installed before the start of the study. An interim analysis was planned after 300 transfusions. All serious adverse events (SAEs) were reviewed by the DSMB. Two criteria for early stopping of an experimental arm were defined: 1. A negative 24-hour CCI (decrement) not caused by immunological factors in more than 20% of the transfusions; 2. Statistically significant more bleeding complications (CTCAE  $\geq 2$ ) compared to the Plasma arm.

## Power calculation and statistical analysis

The study was designed as a one-sided, non-inferiority study comparing the 1-hour CCI of the transfusions in the PR-PASIII arm and in the PASIII arm with the Plasma arm. Inferiority of an experimental arm was defined as a 20% lower mean 1-hour CCI compared to the Plasma arm. A mean 1-hour CCI of 15.6 and a standard deviation of 6.0 were used based on a previous study (Kerkhoffs *et al*, 2006). For a power of 90% and an alpha of 0.025 (multiple testing) 100 patients per arm were required. In case of **multi-dose** transfusions, the sum of the platelet content of the **PC** was used. If one of the PC products differed from the allocated arm, the **multi-dose** transfusion was considered as not according to protocol. The mean of the storage times of the **PC** in a **multi-dose**

transfusion was used as the storage time. The 1 and 24 hour counts after the infusion of the last PC of a **multi-dose** transfusion were used for analysis. To account for the hierarchical structure of the data with a variable number of transfusions per patient, the data were analysed using mixed regression models with random effects for patient and transfusion number. Besides the CCIs, 1 and 24 hour posttransfusion counts were used as endpoints in regression models with as additional covariates besides arm, platelet dose, pretransfusion counts and body surface area of the patient (Davis *et al*, 1999). The data were analysed by intention to treat (ITT) as well as per protocol (PP). To assess safety, the incidence of bleeding complications and adverse reactions were analysed through tabulation. Pearson's chi-square test was used to compare categorical patient characteristics by arm and the Kruskal-Wallis test to compare ordinal or continuous characteristics by arm. A relation between storage time and the post transfusion counts and CCIs was assessed by adding this factor as covariate to the regression models. The association between the patient and transfusion characteristics mentioned above was assessed by adding each of these variables separately as covariate to the regression models. All statistical analyses were performed using Stata.

## Results

### Patients and platelet transfusions

Inclusion of patients started March 2007. The inclusion of patients in the PR-PASIII group was halted after 92 patients in January 2009 on advice of the DSMB because of lower CCI's ( $p < 0.0001$ ) and more bleedings ( $p = 0.045$ ) compared to the plasma group.

1  
2  
3 Inclusion of patients in the plasma and PASIII group ended May 2009 and overall 295  
4 patients were randomised. There were 17 non-evaluable patients, resulting in a total of  
5 278 evaluable patients and 1129 transfusion events (fig 1). There were no significant  
6 differences in the patient characteristics of the study groups (table 1). 302 transfusion  
7 events (27%) were not according to the allocated study arm, more frequent in both study  
8 arms. 85% of the off protocol **PC** were platelets stored in PASII, 15% were platelets  
9 stored in plasma. The study products had a lower platelet content, with a mean difference  
10 of 6% and 11% for PASIII-**PC** and PR-PASIII-**PC** as compared to plasma **PC**,  
11 respectively (table 1,  $p < 0.001$ ).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

#### 27 Platelet transfusion efficacy

28 All efficacy analyses were done ITT as well as PP. The 1-hour CCI and 24-hour CCI  
29 **were** evaluable in 1004 (88.9%) and 1013 (89.7%) of the transfusion events, respectively.  
30  
31 The single reason for a non-evaluable CCI-1/24 was failure to perform a platelet count  
32 after transfusion and with respect to these missing evaluations there were no significant  
33 differences between the study groups or between the per- and off-protocol transfusion  
34 events. All transfusion efficacy parameters show inferiority of transfusions with PR-  
35 PASIII-**PC**. There were no significant differences in transfusion responses between  
36 PASIII-**PC** and Plasma-**PC** (table 2). **The proportion of 6 and 7 days stored PC was**  
37 **equally distributed across the arms, being 24%, 21% and 26% of transfused PC in**  
38 **the plasma arm, the PASIII arm and the PRPASIII arm, respectively** . Both the 1-  
39 hour CCI as well as the 24-hour CCI decreased with longer storage time in all study  
40 **groups. However** both CCIs were significantly less in PR-PASIII-**PC** at each day of  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 storage as compared to plasma **PC** (figs 2A&B). The 1- and 24-hour CCI of PASIII-**PC**  
4 did not differ significantly to plasma **PC** up to 7 days of storage. Linear regression  
5 analysis of 1- and 24-hour platelet count showed a platelet dose independent effect of  
6 pathogen reduction (figs 2C&D, table 3). A number of product and patient related  
7 covariates were tested for **an** association with CCI adjusted for arm (table 4). Storage  
8 time, enlarged spleen and fever were highly significantly associated with lower CCI,  
9 while the use of steroids as premedication was associated with a higher 1-hour CCI and  
10 transfusion for a bleeding indication was associated with a lower 24-hour CCI.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

#### 24 Bleeding and other clinical complications

25  
26 Sixty-seven new bleeding episodes (CTCAE grade 1-3) were observed in 60 patients  
27 during the on study period from the start of the first transfusion with significantly more  
28 ( $p=0.034$ ) and higher grade ( $p=0.044$ ) bleeding in the PR-PASIII group (table 5).  
29 Distribution of bleeding sites was not different between the study groups. 14 of the  
30 bleeding patients were on anticoagulant therapy at the time of bleeding, without  
31 differences between the groups. We did not observe lethal bleeding complications in the  
32 on protocol period; however, one patient in the PR-PASIII arm deceased due to  
33 intracranial bleeding after going off protocol. **We did not find an association between**  
34 **platelet dose, storage time or  $\gamma$ -irradiation and the occurrence of bleeding (all**  
35 **grades).** There were no differences between the groups with regard to number of RBC  
36 transfusions received. **The mean number of RBCs in the plasma group was  $4\pm 3$  as**  
37 **compared to  $5\pm 3$  and  $4\pm 3$  in the PASIII and PR-PASIII group, respectively.**  
38  
39 **Twenty-eight** mostly mild transfusion reactions occurred in 25 patients, without  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 significant differences **between groups** (table 5). **Incidences of infections and SAE's**  
4 **were equally distributed among the groups.** Three SAE's were possibly related to PC  
5  
6 transfusion, one in each group. In the plasma group a patient developed a severe,  
7  
8 generalized skin reaction, in the PASIII arm a possible TRALI was reported and in the  
9  
10 PR-PASIII arm a patient developed acute glottis oedema treated successfully with  
11  
12 **antihistamines and steroids.**  
13  
14  
15  
16  
17  
18  
19

## 20 Discussion

21  
22  
23  
24 In a non-selected population of thrombocytopenic haematology patients we studied the  
25  
26 transfusion efficacy of PR-PASIII-PCs and PASIII-PCs in terms of increments,  
27  
28 transfusion failures, PC consumption and transfusion interval as well as bleeding  
29  
30 occurrence and adverse transfusion reactions, compared to plasma-PC. In accordance  
31  
32 with the SPRINT trial but in contrast to the EuroSPRITE trial, we observed inferiority of  
33  
34 transfusions with PR-PASIII-PC with regard to all transfusion efficacy-related endpoints  
35  
36 (van Rhenen *et al*, 2003; McCullough *et al*, 2004). Moreover more patients in the PR-  
37  
38 PASIII-PC arm experienced bleeding complications. As reported previously, both study  
39  
40 products contained less platelets due to loss of platelets during the production process  
41  
42 (McCullough *et al*, 2004; Kerkhoffs *et al*, 2006; Murphy *et al*, 2006; Pineda *et al*, 2006).  
43  
44  
45  
46 As CCI might not adequately correct for dose differences between arms, we performed  
47  
48 linear regression analysis of the posttransfusion platelet counts with covariates treatment  
49  
50 arm, platelet content and storage time, also showing an independent effect of PR-PASIII  
51  
52 PC (Davis *et al*, 1999). Using the linear regression analysis we estimate that a PR-  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 PASIII-PC should on average contain  $200 \times 10^9$  platelets extra (i.e. approximately 3 BCs)  
4  
5 to achieve a comparable count increment. The relationship between storage time with  
6  
7 both CCIs showed a constant difference at each incremental day of storage, suggesting a  
8  
9 decreased viability of a fixed number of platelets and a normal disappearance of  
10  
11 surviving platelets after treatment with this PR technique. To the same extend as plasma  
12  
13 **PC**, PASIII **PC** show a decrease in transfusion efficacy up to seven days of storage and  
14  
15 no difference in bleeding complications. Our results with regard to lower increments are  
16  
17 in agreement with the SPRINT study. The discordance with the EuroSPRITE as well as  
18  
19 with a large phase IV trial **may be due to** the usage of **PC** stored in PASII **in**  
20  
21 **approximately half** of the reference group attenuating the results of the reference groups  
22  
23 in these other studies (van Rhenen *et al*, 2003; Osselaer *et al*, 2009).  
24  
25  
26  
27  
28

29 Patients in the PR-PASIII group experienced more and more grade  $\geq 2$  bleeding  
30  
31 compared with both **the other** arms. **The** EuroSPRITE and the other smaller European  
32  
33 RCT reported no differences between the study arms with regard to bleeding  
34  
35 complications (van Rhenen *et al*, Janetzko *et al*, 2005). However in the extended safety  
36  
37 report of the SPRINT trial the frequency of grade 2-4 bleeding appeared significantly  
38  
39 higher in the PR-arm, 43% as compared to 34% in the control arm ( $p = 0.02$ ) (Snyder *et*  
40  
41 *al*, 2005). It is unlikely that the difference in bleeding complications **is solely** explained  
42  
43 by a lower platelet dose **resulting in** lower post transfusion **platelet** peak levels.  
44  
45 **Estimating approximately one-third non-viable** platelets in PR-PC, the platelet dose is  
46  
47 **still** comparable with the low to medium dose applied in a recently presented platelet  
48  
49 dose trial showing that bleeding complications did not differ between **low, medium or**  
50  
51 **high dose levels of platelets transfused** (Slichter *et al*, 2010). **Possibly**, damage of  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
platelet mitochondrial nucleic acids by PR may not only result in loss of viability **of a proportion of platelets**, but may impair haemostatic capacity as well (Keuren *et al*, 2006; Apelseth *et al*, 2007). We did not find significant differences in transfusion reactions as observed in larger trials using PR-PASIII **PC** (Osselaer *et al*, 2008a; Osselaer *et al*, 2008b).

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
**This study has some shortcomings.** The number of off-protocol transfusions in the PR-PASIII arm **can** be regarded as an important limitation of our study. However, performances of both an ITT as well as a PP analysis lead to similar conclusions. The open label aspect of our study is not expected to influence platelet counts, the primary endpoint of our study, although we cannot completely exclude bias with regard to evaluation of bleeding.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
In conclusion, although there are clear advantages and arguments in favour of pathogen reduction techniques to increase transfusion safety, our results warrant a reappraisal of pathogen reduction techniques prior to routine implementation. The process of **PR using amotosalen-HCl/UVA** likely leads to decreased platelet viability and perhaps compromises haemostatic function, the primary goal of platelet transfusions in high risk patients. A comprehensive survey on the nature and consequences of **amotosalen-HCl/UVA-induced platelet damage** is needed to understand how this damage can be compensated for in routine transfusion practise.

## 51 52 53 54 55 56 57 58 59 60 **Acknowledgments**

We would like to thank all the physicians, nurses, technologists, data managers and study coordinators at each study site, as well as all the blood bank personnel producing all the

1  
2  
3 products. We also thank Cerus Corporation for support in the production of the PR-  
4  
5 PASIII PCs.  
6  
7

## 10 **References**

- 11  
12  
13  
14  
15 Apelseh, T.O., Bruserud, O., Wentzel-Larsen, T., Bakken, A.M., Bjorsvik, S., Hervig, T.  
16  
17 (2007) In vitro evaluation of metabolic changes and residual platelet responsiveness  
18  
19 in photochemical treated and gamma-irradiated single-donor platelet concentrates  
20  
21 during long-term storage. *Transfusion*, **47**, 653 – 665.  
22  
23  
24  
25 Blajchman, M.A., Beckers, E.A., Dickmeiss, E., Lin, L., Moore, G., Muylle, L. (2005)  
26  
27 Bacterial detection of platelets: current problems and possible resolutions.  
28  
29 *Transfusion Medicine Reviews*, **19**, 259 – 272.  
30  
31  
32 Council of Europe expert committee in blood transfusion study group on pathogen  
33  
34 inactivation of labile blood products. Pathogen inactivation of labile blood products.  
35  
36 (2001) *Transfusion Medicine*, **11**, 149 – 175.  
37  
38  
39 Davis, K.B., Slichter, S.J., Corash, L. (1999) Corrected count increment and percent  
40  
41 platelet recovery as measures of posttransfusion platelet response: problems and a  
42  
43 solution. *Transfusion*, **39**, 586 – 592.  
44  
45  
46 Dodd, R.Y., Notari, E.P., Stramer, S.L. (2002) Current prevalence and incidence of  
47  
48 infectious disease markers and estimated window-period risk in the American Red  
49  
50 Cross blood donor population. *Transfusion*, **42**, 975 – 979.  
51  
52  
53 Goodnough, L.T., Brecher, M.E., Kanter, M.H., AuBuchon, J.P. (1999) Transfusion  
54  
55 medicine: blood transfusion. *New England Journal of Medicine*, **340**, 438 – 447.  
56  
57  
58  
59  
60

- 1  
2  
3 Grass, J.A., Wafa, T., Reames, A., Wages, D., Corash, L., Ferrara, J.L., Lin, L. (1999)  
4  
5 Prevention of Transfusion-Associated Graft-versus-Host Disease by photochemical  
6  
7 treatment. *Blood*, **93**, 3140 – 3147.  
8  
9
- 10 Janetzko, K., Lin, L., Eichler, H., Mayaudon, V., Flament, J., Kluter, H. (2004)  
11  
12 Implementation of the INTERCEPT Blood System for platelets into routine blood  
13  
14 bank manufacturing procedures: evaluation of aphaeresis platelets. *Vox Sanguinis*,  
15  
16 **86**, 239 – 245.  
17  
18
- 19 Janetzko, K., Cazenave, J.P., Klüter, H., Kientz, D., Michel, M., Beris, P., Lioure, B.,  
20  
21 Hastka, J., Marblie, S., Mayaudon, V., Lin, L., Lin, J.S., Conlan, M.G., Flament, J.  
22  
23 (2005) Therapeutic efficacy and safety of photochemically treated aphaeresis  
24  
25 platelets processed with an optimized integrated set. *Transfusion*, **45**, 1443 – 1452.  
26  
27
- 28 Jansen, G.A., van Vliet, H.H., Vermeij, H., Beckers, E.A., Leebeek, F.W., Sonneveld, P.,  
29  
30 van Rhenen, D.J. (2004) Functional characteristics of photochemically treated  
31  
32 platelets. *Transfusion*, **44**, 313 – 319.  
33  
34
- 35 Kerkhoffs, J.L., Eikenboom, J.C., Schipperus, M.S., van Wordragen-Vlaswinkel, R.J.,  
36  
37 Brand, R., Harvey, M.S., de Vries, R.R., Barge, R., van Rhenen, D.J., Brand, A.  
38  
39 (2006) A multicenter randomized Study of the efficacy of transfusions with platelet  
40  
41 stored in platelet additive solution II versus plasma. *Blood*, **108**, 3210 – 3215.  
42  
43
- 44 Keuren, J.F., Cauwenberghs, S., Heeremans, J., de Kort, W., Heemskerk, J.W., Curvers,  
45  
46 J. (2006) Platelet ADP response deteriorates in synthetic storage media.  
47  
48 *Transfusion*, **46**, 204 – 212.  
49  
50
- 51 Kuehnert, M., Roth, V., Haley, N. (2001) Transfusion-transmitted bacterial infection in  
52  
53 the United States, 1998 – 2000. *Transfusion*, **41**, 1493 - 1499.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Lee, C.K., Ho, P.L., Lee, K.Y., Cheng, W.W., Chan, N.K., Tsoi, W.C., Lin, C.K. (2003)  
4  
5 Estimation of bacterial risk in extending the shelf life of PLT concentrates from 5 to  
6  
7 7 days. *Transfusion*, **43**, 1047 – 1052.  
8  
9
- 10 Lin, L. (2001) Inactivation of cytomegalovirus in platelet concentrates using Helinx  
11  
12 technology. *Seminars in haematology*, **38**, 27 – 33.  
13  
14
- 15 Lin, L., Dikeman, R., Molini, B., Lukehart, S.A., Lane, R., Dupuis, K., Metzler, P.,  
16  
17 Corash, L. (2004) Photochemical treatment of platelet concentrates with amotosalen  
18  
19 and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic  
20  
21 bacteria. *Transfusion*, **44**, 1496 – 1504.  
22  
23
- 24 Lin, L., Hanson, C.V., Alter, H.J., Jauvin, V., Bernard, K.A., Murthy, K.K., Metzler, P.,  
25  
26 Corash, L. (2005) Inactivation of viruses in platelet concentrates by photochemical  
27  
28 treatment with amotosalen and long-wavelength ultraviolet light. *Transfusion*, **45**,  
29  
30 580 – 590.  
31  
32
- 33  
34 Lozano, M., Galan, A., Mazzara, R., Corash, L., Escolar, G. (2007) Leukoreduced buffy-  
35  
36 coat derived platelet concentrates photochemically treated with amotosalen HCl and  
37  
38 ultraviolet A light stored up 7 days: assessment of hemostatic function under flow  
39  
40 conditions. *Transfusion*, **47**, 666 – 671.  
41  
42
- 43 McCullough, J., Vesole, D.H., Benjamin, R.J., Slichter, S.J., Pineda, A., Snyder, E.,  
44  
45 Stadtmauer, E.A., Lopez-Plaza, I., Coutre, S., Strauss, R.G., Goodnough, L.T.,  
46  
47 Friley, J.L., Raife, T., Cable, R., Murphy, S., Howard, F. 4th, Davis, K., Lin, J.S.,  
48  
49 Metzler, P., Corash, L., Koutsoukos, A., Lin, L., Buchholz, D.H., Conlan, M.G.  
50  
51 (2004) Therapeutic efficacy and safety of platelets treated with a photochemical  
52  
53 process for pathogen inactivation: the SPRINT Trial. *Blood*, **104**, 1534 – 1541.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 van der Meer, P.F., Kerkhoffs, J.L., Curvers, J., Scharenberg, J., de Korte, D., Brand, A.,  
4  
5 de Wildt-Eggen, J. (2009) In vitro comparison of platelet storage in plasma and in  
6  
7 four platelet additive solutions, and the effect of pathogen reduction: a proposal for  
8  
9 an in vitro rating system. *Vox Sanguinis*, DOI: 10.1111/j.1423-0410.2009.01283.x  
10  
11  
12 Murphy, S., Snyder, E., Cable, R., Slichter, S.J., Strauss, R.G., McCullough, J., Lin, J.S.,  
13  
14 Corash, L., Conlan, M.G. (2006) Platelet dose consistency and its effect on the  
15  
16 number of platelet transfusions for support of thrombocytopenia: an analysis of the  
17  
18 SPRINT trial of platelets photochemically treated with amotosalen HCl and  
19  
20 ultraviolet A light. *Transfusion*, **46**, 24 – 33.  
21  
22  
23  
24 Osselaer, J.C., Messe, N., Hervig, T., Bueno, J., Castro, E., Espinosa, A., Accorsi, P.,  
25  
26 Junge, K., Jacquet, M., Flament, J., Corash, L. (2008a) A prospective observational  
27  
28 cohort safety study of 5106 platelet transfusions with components prepared with  
29  
30 photochemical pathogen inactivation treatment. *Transfusion*, **48**, 1061 – 1071.  
31  
32  
33  
34 Osselaer, J.C., Cazenave, J.P., Lambermont, M., Garraud, O., Hidajat, M., Barbolla, L.,  
35  
36 Tardivel, R., Defoin, L., Waller, C., Mendel, I., Raidot, J.P., Kandel, G., De Meuter,  
37  
38 R., Fabrigli, P., Dehenau, D., Arroyo, J.L., Padrón, F., Gouezec. H., Corral, M.,  
39  
40 Jacquet, M., Sundin, D., Lin, L., Corash, L. (2008b) An active haemovigilance  
41  
42 programme characterizing the safety profile of 7437 platelet transfusions prepared  
43  
44 with amotosalen photochemical treatment. *Vox Sanguinis*, **94**, 315 – 323.  
45  
46  
47  
48 Osselaer, J.C., Doyen, C., Defoin, L., Debry, C., Goffaux, M., Messe, N., Van  
49  
50 Hooydonk, M., Bosly, A., Lin, J.S., Lin, L., Corash, L. (2009) Universal adoption  
51  
52 of pathogen inactivation of platelet components: impact on platelet and red blood  
53  
54 cell component use. *Transfusion*, **49**, 1412 – 1422.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Picker, S.M., Speer, R., Gathof, B.S. (2004) Functional characteristics of buff-coat PLTs  
4 photochemically treated with amotosalen-HCl for pathogen inactivation.  
5  
6  
7  
8 *Transfusion*, **44**, 320 – 329.  
9
- 10 Pineda, A., McCullough, J., Benjamin, R.J., Cable, R., Strauss, R.G., Burgstaler, E.,  
11  
12 Porter, S., Lin, L., Metzel, P., Conlan, M.G. (2006) Pathogen inactivation of  
13 platelets with a photochemical treatment with amotosalen HCl and ultraviolet light:  
14 process used in the SPRINT trial. *Transfusion*, **46**, 562 – 571.  
15  
16  
17
- 18 Van Rhenen, D.J., Vermeij, J., Mayaudon, V., Hind, C., Lin, L., Corash, L. (2000)  
19  
20 Functional characteristics of S-59 photochemically treated platelet concentrates  
21 derived from buffy coats. *Vox Sanguinis*, **79**, 206 – 214.  
22  
23  
24
- 25 van Rhenen, D., Gulliksson, H., Cazenave, J.P., Pamphilon, D., Ljungman, P., Klüter, H.,  
26  
27 Vermeij, H., Kappers-Klunne, M., de Greef, G., Laforet, M., Lioure, B., Davis, K.,  
28  
29 Marblie, S., Mayaudon, V., Flament, J., Conlan, M., Lin, L., Metzel, P., Buchholz,  
30  
31 D., Corash, L (2003) Transfusion of pooled buffy coat platelet components  
32 prepared with photochemical pathogen inactivation treatment: the euro SPRITE  
33 trial. *Blood*, **101**, 2426 – 2433.  
34  
35  
36  
37  
38  
39
- 40 Schrezenmeier, H., Walther-Wenke, G., Müller, T.H., Weinauer, F., Younis, A., Holland-  
41  
42 Letz, T., Geis, G., Asmus, J., Bauerfeind, U., Burkhart, J., Deitenbeck, R.,  
43  
44 Förstemann, E., Gebauer, W., Höchsmann, B., Karakassopoulos, A., Liebscher,  
45  
46 U.M., Sängler, W., Schmidt, M., Schunter, F., Sireis, W., Seifried. E. (2007)  
47  
48 Bacterial contamination of platelet concentrates: results of a prospective multicenter  
49 study comparing pooled whole blood-derived platelets and apheresis platelets.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Simonsen, A.C., Johansson, P.I., Conlan, M.G., Jacquet, M., Lin, J.S., Junge, K., Lin, L.,  
4  
5 Sørensen, H., Borregaard, N., Flament, J. (2006) Transfusion of 7-day old  
6  
7 amotosalen photochemically treated buffy-coat platelets to patients with  
8  
9 thrombocytopenia: a pilot study. *Transfusion*, **46**, 424 – 433.
- 10  
11  
12 Slichter, S.J., Raife, T.J., Davis, K., Rheinschmidt, M., Buchholz, D.H., Corash, L.,  
13  
14 Conlan, M.G. (2006) Platelets photochemically treated with amotosalen HCl and  
15  
16 ultraviolet A light correct prolonged bleeding times in patients with  
17  
18 thrombocytopenia. *Transfusion*, **46**, 731 – 740.
- 19  
20  
21 Slichter, S.J. (2007) Platelet transfusion therapy. *Hematology / Oncology Clinics of North*  
22  
23 *America*, **21**, 697 – 729.
- 24  
25  
26  
27 Slichter, S.J., Kaufman, R.M., Assmann, S.F., McCullough, J., Triulzi, D.J., Strauss,  
28  
29 R.G., Gernsheimer, T.B., Ness, P.M., Brecher, M.E., Josephson, C.D., Konkle,  
30  
31 B.A., Woodson, R.D., Ortel, T.L., Hillyer, C.D., Skerret, D.L., McCrae, K.R.,  
32  
33 Sloan, S.R., Uhl, L., George, J.N., Aquino, V.M., Manno, C.S., McFarland,  
34  
35 J.G., Hess, J.R., Leissinger, C., Granger, S. (2010) Dose of Prophylactic  
36  
37 Platelet Transfusions and Prevention of Hemorrhage. *New England Journal of*  
38  
39 *Medicine*, **362**, 600 – 613.
- 40  
41  
42  
43 Snyder, E., Raife, T., Lin, L., Cimino, G., Metzler, P., Rheinschmidt, M., Baril, L., Davis,  
44  
45 K., Buchholz, D.H., Corash, L., Conlan, M.G. (2004) Recovery and life span of  
46  
47 <sup>111</sup>Indium-radiolabeled platelets treated with pathogen inactivation with amotosalen  
48  
49 HCl (S-59) and ultraviolet light. *Transfusion*, **44**, 1732 – 1740.
- 50  
51  
52  
53 Snyder, E., McCullough, J., Slichter, S.J., Strauss, R.G., Lopez-Plaza, I., Lin, J.S.,  
54  
55 Corash, L., Conlan, M.G. (2005) Clinical safety of platelets photochemical treated  
56  
57  
58  
59  
60

1  
2  
3 with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT  
4  
5 trial. *Transfusion*, **45**, 1864 – 1875.  
6  
7

8 Stroncek, D.F., Rebullia P. (2007) Platelet transfusions. *Lancet*, **370**, 427 – 438.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review



**Table 1** Characteristics of patients and transfusions

	<b>Plasma</b>	<b>PAS III</b>	<b>PR-PAS III</b>
No. of patients	<b>99</b>	<b>94</b>	<b>85</b>
Male / Female	52 / 47	53 / 41	47 / 38
Age, years $\pm$ SD	54 $\pm$ 12	55 $\pm$ 12	53 $\pm$ 12
Body surface area, m <sup>2</sup> $\pm$ SD	1.93 $\pm$ 0.22	1.94 $\pm$ 0.19	1.96 $\pm$ 0.25
Enlarged spleen N (%) <sup>1</sup>	10 (10)	5 (5)	6 (7)
Diagnosis N (%)			
AML / MDS	42 (42)	52 (55)	44 (52)
ALL	9 (9)	4 (4)	3 (4)
Lymphoma	22 (22)	14 (15)	18 (21)
Multiple myeloma	22 (22)	21 (22)	17 (20)
Other	4 (4)	3 (3)	3 (4)
Therapy N (%)			
Remission induction	47 (47)	46 (49)	39 (46)
Consolidation	5 (5)	6 (6)	3 (4)
Autologous transplantation	32 (32)	31 (33)	33 (39)
Allogeneic transplantation	12 (12)	5 (5)	6 (7)
Other	3 (3)	6 (6)	4 (5)
Transfusion history N (%)			
RBC concentrates	55 (56)	59 (63)	43 (51)
PCs	48 (48)	61 (65)	41 (48)
<b>No. of PC transfusion events</b>	<b>357</b>	<b>381</b>	<b>391</b>
Product type according to protocol (%)	292 (82)	278 (73) <sup>2</sup>	257 (66) <sup>2</sup>
<b>Multi-dose</b> transfusion (%)	14 (4)	12 (3)	11 (3)
PC transfusion indication N (%)			
Prophylactic, trigger based	304 (85)	334 (88)	327 (84)
Intervention	38 (11)	25 (7)	44 (11)
Treatment of bleeding complication	11 (3)	19 (5)	16 (4)
Unknown	4 (1)	3 (1)	4 (1)
Platelet product content, mean $\times 10^{11} \pm$ SD	3.9 $\pm$ 1.0	3.6 $\pm$ 0.8 <sup>2</sup>	3.4 $\pm$ 0.8 <sup>2</sup>
Storage time, mean days $\pm$ SD	4.0 $\pm$ 1.8	3.8 $\pm$ 1.8	4.0 $\pm$ 1.6
Pre transfusion PLT count $\times 10^9/L \pm$ SD	18 $\pm$ 13	17 $\pm$ 13	16 $\pm$ 11 <sup>3</sup>

<sup>1</sup>Number (%) of evaluable patients and transfusions; <sup>2</sup>p < 0.001 as compared to plasma; <sup>3</sup>p = 0.04 as compared to plasma; AML = Acute myeloid leukaemia; MDS = Myelodysplastic syndrome; ALL = Acute lymphoblastic leukaemia; RBC = Red blood cell; PC = Platelet concentrate. Major ABO-incompatibility occurred in only 6 PC transfusions.

**Table 2** Transfusion response parameters: ITT and according to protocol (PP)

No. of patients	Plasma 99	PAS III 94	PR-PAS III 85
<b>ITT analysis</b>			
CCI-1 hour, mean $\pm$ SD	17.1 $\pm$ 7.3	15.3 $\pm$ 6.5	11.4 $\pm$ 5.3 <sup>5</sup>
Mean diff (97.5% CI) <sup>1</sup>		-9% (-22%; 4%)	-31% (-43%; -18%)
CCI-24 hour, mean $\pm$ SD	12.8 $\pm$ 7.8	11.6 $\pm$ 7.6	7.9 $\pm$ 5.3 <sup>5</sup>
Mean diff (97.5% CI) <sup>1</sup>		-7% (-26%; 12%)	-34% (-52%; -17%)
<b>PP analysis</b>			
CCI-1 hour, mean $\pm$ SD	17.1 $\pm$ 7.3	15.3 $\pm$ 6.7	10.6 $\pm$ 5.0 <sup>5</sup>
Mean diff (97.5% CI) <sup>1</sup>		-10% (-23%; 4%)	-36% (-49%; -24%)
CCI-24 hour, mean $\pm$ SD	12.5 $\pm$ 7.7	11.7 $\pm$ 7.6	6.8 $\pm$ 5.9 <sup>5</sup>
Mean diff (97.5% CI) <sup>1</sup>		-4% (-24%; 16%)	-42% (-61%; -23%)
<b>Other response parameters (ITT)</b>			
CI-1 hour, mean $\times 10^9/L \pm$ SD	34 $\pm$ 15	29 $\pm$ 13	20 $\pm 10^4$
CI-24 hour, mean $\times 10^9/L \pm$ SD	25 $\pm$ 15	21 $\pm$ 13	14 $\pm 10^3$
PC transfusions / patient, mean $\pm$ SD	4 $\pm$ 2	4 $\pm$ 3	5 $\pm 3^2$
TRF interval (hours), mean $\pm$ SD	81 $\pm$ 47	77 $\pm$ 44	61 $\pm 47^3$
<b>Transfusion failure (ITT)</b>			
n of Evaluable CCI-1	<b>314</b>	<b>340</b>	<b>350</b>
CCI-1 hour < 7.5 (%) <sup>6</sup>	48 (15)	66 (19)	97 (28) <sup>5</sup>
n of Evaluable CCI-24	<b>319</b>	<b>343</b>	<b>351</b>
CCI-24 hour < 4.5 (%) <sup>6</sup>	72 (23)	94 (27)	125 (36) <sup>3</sup>

The mean CCI and CI values were calculated as the mean of the average CCI/CI of all transfusions per patient. <sup>1</sup> Mean difference with 97.5% confidence interval of PAS III and PR-PAS III compared to Plasma derived from mixed model regression analyses. <sup>2</sup>  $p < 0.05$ , <sup>3</sup>  $p < 0.01$ , <sup>4</sup>  $p < 0.001$ , <sup>5</sup>  $p < 0.0001$  as compared to plasma; <sup>6</sup> percentage of evaluable CCIs.

**Table 3** Linear regression analysis 1- and 24-hour PLT counts

	1-hour PLT count		24-hour PLT count	
	Beta <sup>1</sup>	p-value	Beta	p-value
PASIII	-2.29	0.377	1.79	0.507
PR-PASIII	-9.63	0.001	-8.95	0.003
Storage time (days)	-1.55	<0.001	-1.24	<0.001
Body surface area (m <sup>2</sup> )	-15.4	<0.001	-10.1	0.002
Transfusion sequence number	-0.38	0.047	-0.08	0.686
Platelet product content (x 10 <sup>9</sup> )	0.09	<0.001	0.06	<0.001
Precount (x 10 <sup>9</sup> /l)	0.96	<0.001	0.96	<0.001

<sup>1</sup>Beta: regression coefficient. Multivariate linear regression analyses with patient as random factor and as dependent variables the 1-hour platelet (columns 2 and 3) and the 24-hour platelet count (columns 4 and 5). The factors included in the models are shown in the first column. The estimated regression coefficients are shown in the Beta -columns. The regression coefficients measure the strength of the effect per unit change of the corresponding factor; e.g the 1-hour platelet count decreases on average with 1.55 x 10<sup>9</sup>/l with each additional day of storage, while an increase of the content of the platelet product with 1 x 10<sup>9</sup> results on average in an increase of 0.09 x 10<sup>9</sup>/l of the 1-hour platelet count. The regression coefficients for PAS III and PR-PAS III indicate the average difference in the post transfusion counts as compared to Plasma.

**Table 4** Relation between covariates and the CCI-1 and CCI-24 adjusted for arm

	1-hour CCI		24-hour CCI	
	Beta <sup>1</sup> (SE)	p-value	Beta (SE)	p-value
Storage time (days)	<b>-0.9 (0.1)</b>	<b>&lt;0.00001</b>	<b>-0.9 (0.1)</b>	<b>&lt;0.00001</b>
Spleen enlargement	<b>-5.7 (1.4)</b>	<b>&lt;0.00001</b>	<b>-6.5 (1.5)</b>	<b>&lt;0.00001</b>
Fever	<b>-1.7 (0.4)</b>	<b>&lt;0.00001</b>	<b>-1.5 (0.4)</b>	<b>0.0003</b>
Steroids	<b>2.6 (1.1)</b>	<b>0.02</b>	1.0 (1.3)	0.43
Indication bleeding	1.1 (1.0)	0.29	<b>-2.5 (1.1)</b>	<b>0.02</b>
Indication Intervention	-0.6 (0.8)	0.39	-0.4 (0.8)	0.64
Age (years)	0.2 (0.3)	0.49	0.0 (0.3)	0.97
Sex	1.1 (0.8)	0.17	0.3 (0.8)	0.76
Prior PLT TRF	-1.0 (0.8)	0.22	-1.0 (0.8)	0.24
Prior RBC TRF	-0.9 (0.8)	0.25	-0.7 (0.8)	0.42
Prior TRF reactions	-2.4 (1.5)	0.12	-0.3 (1.7)	0.84
Infection	-0.5 (0.5)	0.33	-0.5 (0.5)	0.27
Mucosal damage	-0.1 (0.5)	0.82	0.1 (0.5)	0.82
ABO mismatch	0.2 (0.4)	0.68	0.4 (0.4)	0.33
<b>Anti-histamines</b>	<b>-1.6 (1.3)</b>	<b>0.21</b>	<b>-1.8 (1.3)</b>	<b>0.16</b>
Anti-coagulation	-1.3 (1.3)	0.31	-2.1 (1.4)	0.14
Acetaminophen	1.1 (1.3)	0.39	-1.3 (1.3)	0.31

Univariate random effects regression analysis adjusted for arm. <sup>1</sup>Beta: regression coefficient; SE = Standard error; TRF = Platelet transfusion; RBC = Red blood cell concentrate. All covariates, with the exception of storage time and patient age, are no/yes covariates.

**Table 5** Bleeding, transfusion reactions, infections and SAE's

<b>No. of patients</b>	<b>Plasma 99</b>	<b>PAS III 94</b>	<b>PR-PAS III 85</b>
<b>Bleeding after first PC transfusion</b>			
No of patients (%)	19 (19)	14 (15)	27 (32) <sup>1</sup>
No of episodes	19	16	32
Maximum grade (%)			
Grade 1	12 (12)	10 (11)	16 (19)
Grade 2	6 (6)	4 (4)	6 (7)
Grade 3	1 (1)	-	5 (6)
<b>Patients with transfusion reactions, N (%)</b>	11 (11)	8 (9)	6 (7)
<b>No. of transfusion reactions</b>	13	8	7
Severity of events			
No or minor morbidity	11	7	6
Moderate morbidity	1	-	1
Serious morbidity	1	1	-
<b>Patients with infectious complications, N (%)</b>	40 (40)	39 (41)	42 (49)
Maximum grade (%)			
Grade 1 (%)	1	-	-
Grade 2 (%)	3	5	6
Grade 3 (%)	30	29	28
Grade 4 (%)	6	4	8
Grade 5 (%)	-	1	-
<b>Immunological Refractoriness, N (%)</b>	2 (2)	-	2 (2)
<b>Serious adverse events, N</b>	7	3	5
SAE related to PC transfusion	1	1	1
<b>Death, N</b>	3 <sup>2</sup>	1	3

Except for the number of bleeding episodes, the numbers in the table reflect numbers (percentage) of patients. For the grades of bleeding and infections the maximum grade is used in case of more than one bleeding episode or more than one infection. <sup>1</sup> p = 0.034 as compared to plasma; <sup>2</sup> 1 patient died in the plasma arm 24 days after the last transfusion (the fifth) without SAE report. The cause of death was reported on the off study form as related to the treatment of the underlying disease, with fever presumably due to sepsis.




Figure 1 shows the randomisation scheme together with evaluable patients, transfusions and endpoints. n = number of patients, n PC = number of single platelet concentrates, n TRF = number of PC transfusion events (includes pooled transfusions). Of the 17 non-evaluable patients 4 patients were non-eligible due to anti-HLA antibodies and 13 patients did not receive any platelet transfusions, without differences between study groups.

297x209mm (200 x 200 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2 shows the fitted lines from linear regression analyses restricted to per protocol transfusions. Black, blue and red, respectively represent Plasma, PAS III and PR-PAS III. (2A/B) The 1-hr and 24-hr CCI as function of storage time for the three treatment groups. Point estimates with 95% confidence intervals and number of transfusions are indicated. The lines are the fitted lines assuming a linear relation between CCI and storage time for each group. (2C/D) Fitted 1-hr and 24-hr increments as linear functions of storage time for the three treatment groups for a patient with surface area 1.93, precount 12 and storage time of 4 days. Standard error bars are indicated.

645x516mm (96 x 96 DPI)